APS03118 是一种口服有效、强效且高选择性的转染重排 (RET) 抑制剂,广谱抑制 RET 融合及多种突变(包括 G810、V804、L730 和 Y806 变体),IC50 值普遍低于 1 nM(对野生型的 IC50 为 0.0952 nM;对突变体的 IC50 范围为 0.00438 至 5.72 nM),并对 RET G810 突变展现出显著的抑制活性,能有效抑制整个 RET 信号通路(包括 RET、Shc 和 ERK1/2),对大多数脱靶激酶具有超过 20 倍的选择性(FLT3 和 YES 除外),在体内模型中可在 KIF5B-RET 和 CCDC6-RET V804M PDX 小鼠模型中诱导肿瘤完全消退,并显著延长颅内 CCDC6-RET 转移小鼠模型中的生存期,可用于针对选择性 RET 抑制剂 (SRI) 耐药的 RET 驱动型癌症的相关研究。
产品编号: MS-A77127 CAS No.: 2598870-24-5 分子式: C27H28N8O2 分子量: 496.56
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

APS03118 是一种口服有效、强效且高选择性的转染重排 (RET) 抑制剂,广谱抑制 RET 融合及多种突变(包括 G810、V804、L730 和 Y806 变体),IC50 值普遍低于 1 nM(对野生型的 IC50 为 0.0952 nM;对突变体的 IC50 范围为 0.00438 至 5.72 nM),并对 RET G810 突变展现出显著的抑制活性,能有效抑制整个 RET 信号通路(包括 RET、Shc 和 ERK1/2),对大多数脱靶激酶具有超过 20 倍的选择性(FLT3 和 YES 除外),在体内模型中可在 KIF5B-RET 和 CCDC6-RET V804M PDX 小鼠模型中诱导肿瘤完全消退,并显著延长颅内 CCDC6-RET 转移小鼠模型中的生存期,可用于针对选择性 RET 抑制剂 (SRI) 耐药的 RET 驱动型癌症的相关研究。

生物实验数据

生物活性 APS03118 is an orally active, potent, and highly selective rearranged during transfection (RET) inhibitor that broadly inhibits RET fusions and multiple mutations (including G810, V804, L730, and Y806 variants) with IC50 values generally below 1 nM (IC50 of 0.0952 nM for wild-type; IC50 range of 0.00438 to 5.72 nM for mutants) and exhibits significant inhibitory activity against RET G810 mutation, effectively inhibits the entire RET signaling pathway (including RET, Shc, and ERK1/2), displays greater than 20-fold selectivity over most off-target kinases (except FLT3 and YES), induces complete tumor regression in KIF5B-RET and CCDC6-RET V804M PDX mouse models and significantly prolongs survival in an intracranial CCDC6-RET metastasis mouse model in vivo, and can be used for research on RET-driven cancers resistant to selective RET inhibitors (SRIs).
体外研究
(In Vitro)

APS03118 (compound 5) 对 RET 溶剂前沿 G810 突变的抑制活性显著优于 Selpercatinib (MS-N43718) 和 Pralsetinib (MS-W42028)。
APS03118 对 ERT 耐药突变 (如溶剂前沿和守门员突变) 展示出卓越疗效,并且在天然 RET 融合阳性 LC2/ad 肺癌细胞中表现出与 Pralsetinib 和 Selpercatinib 相当的强效抗增殖活性 (IC50 = 10.08 nM)。
APS03118 (0-3000 nM) 可强效抑制 Ba/F3 KIF5B-RET、Ba/F3 KIF5B-RET V804M、Ba/F3 KIF5B-RET G810R 和 Ba/F3 KIF5B-RET M918T 细胞中的 RET 自身磷酸化,IC50 值分别为 1.91、1.18、14.66 和 2.28 nM。
APS03118 (0-1000 nM,1.5 小时) 在低纳摩尔浓度下即可有效抑制 TT-RET C634W 细胞中的整个 RET 信号通路 (包括 RET、Shc 和 ERK1/2)。

Western Blot Analysis

Cell Line: TT-RET C634W cells
Concentration: 0, 1, 10, 100, and 1000 nM
Incubation Time: 1.5 h
Result: Almost abolished the phosphorylation of RET, Shc and ERK1/2 at 10 nM, whereas Selpercatinib and Pralsetinib only partially inhibited it.
Inhibited the phosphorylation of RET, Shc, and ERK1/2 at concentrations below 10 nM.
体内研究
(In Vivo)

APS03118 (3、10 和 30 mg/kg,口服,每日两次,连续 28 天) 在 KIF5B-RET 和 CCDC6-RET V804M PDX 小鼠模型中均展现出强效的抗肿瘤作用。
APS03118 (10 和 30 mg/kg,口服,每日两次,连续 90 天) 在颅内 CCDC6-RET 转移小鼠模型中可清除颅内肿瘤并延长生存期。
APS03118 (10 和 30 mg/kg,口服,每日两次,连续 14 或 15 天) 在 Ba/F3 KIF5B-RET G810R 和 Ba/F3 KIF5B-RET V804M CDX 小鼠模型中可抑制肿瘤生长。

Animal Model: Female BALB/c nude mice (6-8 weeks) subcutaneously implanted with KIF5B-RET tumors
Dosage: 3, 10 and 30 mg/kg
Administration: p.o., BID for 28 days
Result: Inhibited tumor growth in a dose-dependent manner, with TGI of 85, 107, and 109% at 3, 10, and 30 mg/kg, respectively.
Significantly reduced tumor volumes on day 17 compared to the vehicle.
Achieved complete tumor regression at 10 and 30 mg/kg at the study end point, matching the efficacy of Selpercatinib at its 10 mg/kg dose.
Revealed no significant body weight changes.
Animal Model: Female BALB/c nude mice (6-8 weeks) subcutaneously implanted with CCDC6-RET V804M tumors
Dosage: 3, 10 and 30 mg/kg
Administration: p.o., BID for 28 days
Result: Achieved tumor growth inhibition of 88, 99, and 100%, at 3, 10, and 30 mg/kg, respectively.
Reduced tumor volumes in all tested group.
Reduced tumor size at 3 and 10 mg/kg, with efficacy comparable to Selpercatinib at its 10 mg/kg dose.
Revealed no significant body weight changes.
Animal Model: Female BALB/c nude mice (6-8 weeks) intracranially implanted with CCDC6-RET tumors into the brain
Dosage: 10 and 30 mg/kg
Administration: p.o., BID for 90 days
Result: Significantly prolonged the survival time and demonstrated a 100% survival rate at a dose of 10 mg/kg.
Induced complete regression of brain tumors at 10 and 30 mg/kg.
Animal Model: Female BALB/c nude mice (6-8 weeks) subcutaneously injected with Ba/F3 KIF5B-RET G810R cells
Dosage: 10 and 30 mg/kg
Administration: p.o., BID for 15 days
Result: Induced potent tumor growth inhibition with a TGI of 90% at 30 mg/kg, while Selpercatinib achieved only 48% TGI at the same dose.
Exhibited greater efficacy than Selpercatinib in slowing the growth of Ba/F3 KIF5B-RET G810R allograft tumors at the same dose.
Exhibited excellent tolerability at 10 and 30 mg/kg, with no significant body weight loss or apparent abnormalities in mice.
Significantly reduced tumor volume compared to control on day 11.
Animal Model: Female BALB/c nude mice (6-8 weeks) subcutaneously injected with Ba/F3 KIF5B-RET V804M cells
Dosage: 10 mg/kg
Administration: p.o., BID for 14 days
Result: Achieved considerably higher TGI rates of 61% compared to Selpercatinib (10 mg/kg, p.o., BID; TGI = 48%).
Was well-tolerated with no significant body weight loss in mice compared to the vehicle group during the treatment period.

化学信息

分子量 496.56
分子式 C27H28N8O2
CAS No. 2598870-24-5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础